Invesco Ltd. Has $201,000 Stock Holdings in Bioventus Inc. (NYSE:BVS)

Invesco Ltd. cut its position in Bioventus Inc. (NYSE:BVS - Free Report) by 94.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,096 shares of the company's stock after selling 323,850 shares during the period. Invesco Ltd.'s holdings in Bioventus were worth $201,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. HighTower Advisors LLC lifted its holdings in Bioventus by 11.3% during the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company's stock worth $143,000 after acquiring an additional 1,380 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Bioventus by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company's stock valued at $202,000 after purchasing an additional 1,652 shares in the last quarter. Plato Investment Management Ltd acquired a new position in shares of Bioventus in the 4th quarter valued at approximately $38,000. Wells Fargo & Company MN increased its stake in Bioventus by 32.0% during the 4th quarter. Wells Fargo & Company MN now owns 22,494 shares of the company's stock worth $236,000 after purchasing an additional 5,459 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in Bioventus during the 4th quarter worth approximately $75,000. 62.94% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares in the company, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Mark Leonard Singleton sold 3,875 shares of the company's stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the completion of the sale, the chief financial officer now owns 141,088 shares in the company, valued at $1,068,036.16. This represents a 2.67 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,208 shares of company stock worth $226,138. 32.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on BVS. Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 price target on shares of Bioventus in a report on Monday, March 17th. Craig Hallum set a $15.00 target price on Bioventus and gave the stock a "buy" rating in a report on Wednesday.

Bioventus Stock Up 5.6 %

Shares of BVS traded up $0.35 during mid-day trading on Wednesday, hitting $6.55. 668,712 shares of the company's stock were exchanged, compared to its average volume of 464,682. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 52 week low of $4.51 and a 52 week high of $14.38. The company has a market cap of $536.73 million, a PE ratio of -10.74 and a beta of 0.95. The company has a 50-day simple moving average of $8.61 and a 200 day simple moving average of $10.20.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.